Stock listing

BIVA:CABA Cabaletta Bio, Inc. Acciones

Mexican listing (BIVA) of Cabaletta Bio, Inc. · home listing NASDAQ:CABA

Follow Cabaletta Bio, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:CABA

$0.936 USD -0.119 (-11.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CABA

Past year -56.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.930 – $1.030 USDNov 20, 2026
Volume
3.73M sharesNov 20, 2026
Market cap
$201.9M USDAt the close on Nov 20, 2026 · price × 215.7M shares outstanding
52-week range
$0.930 – $4.230 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$11.03M USDMedian day 5.23M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cabaletta Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CABA · Home$0.936 USD-0.119 (-11.3%)3,730,726$0.990$1.030$0.930$1.055Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CABA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.936-0.119-11.3%$0.990$1.030$0.9303,730,726
$1.055+0.035+3.4%$1.040$1.120$1.0354,133,935
$1.020-0.090-8.1%$1.090$1.160$0.9825,455,620
$1.110-0.170-13.3%$1.250$1.250$1.1005,234,740
$1.280-0.050-3.8%$1.340$1.350$1.2503,217,950
$1.330-0.120-8.3%$1.430$1.460$1.3303,731,150
$1.4500.0000.0%$1.460$1.520$1.3753,763,705
$1.450-0.050-3.3%$1.480$1.537$1.4103,601,225
$1.500+0.200+15.4%$1.370$1.550$1.3708,165,908
$1.300+0.020+1.6%$1.270$1.330$1.2502,997,368
$1.280-0.140-9.9%$1.410$1.430$1.1806,245,584
$1.4200.0000.0%$1.498$1.520$1.4003,156,536
$1.420-0.010-0.7%$1.430$1.495$1.4002,857,405
$1.430-0.080-5.3%$1.520$1.540$1.3805,685,540
$1.510-0.075-4.7%$1.540$1.585$1.4303,727,617
$1.585+0.065+4.3%$1.540$1.630$1.5405,382,972
$1.520+0.065+4.5%$1.440$1.530$1.4205,829,617
$1.455+0.105+7.8%$1.350$1.455$1.3206,630,771
$1.350-0.120-8.2%$1.460$1.470$1.3206,235,769
$1.470-0.050-3.3%$1.500$1.500$1.3903,991,692
$1.520-0.020-1.3%$1.530$1.555$1.4852,240,356
$1.540-0.070-4.3%$1.610$1.635$1.5103,046,305
$1.610+0.130+8.8%$1.513$1.630$1.4503,462,663
$1.480+0.070+5.0%$1.425$1.500$1.3904,556,472
$1.410-0.140-9.0%$1.560$1.620$1.4006,674,200
$1.550-0.070-4.3%$1.610$1.625$1.5206,741,600
$1.620-0.070-4.1%$1.640$1.680$1.5056,235,700
$1.690-0.100-5.6%$1.790$1.820$1.5907,935,400
$1.790-0.140-7.3%$1.940$1.940$1.7804,830,000
$1.930-0.020-1.0%$1.940$1.980$1.9002,592,700
$1.950-0.020-1.0%$1.960$1.970$1.8705,942,300
$1.970-0.050-2.5%$1.980$2.060$1.9412,141,800
$2.020-0.060-2.9%$2.100$2.138$1.9604,127,200
$2.080+0.080+4.0%$2.010$2.120$1.9555,407,200
$2.000+0.110+5.8%$1.940$2.010$1.8305,705,700
$1.890-0.030-1.6%$1.920$1.970$1.8608,533,800
$1.920-0.060-3.0%$2.010$2.010$1.9008,051,400
$1.980-0.020-1.0%$2.010$2.030$1.9504,192,200
$2.000-0.070-3.4%$2.060$2.070$1.9805,436,200
$2.070-0.085-3.9%$2.170$2.170$2.0503,096,200
$2.155-0.065-2.9%$2.230$2.230$2.0605,589,900
$2.220-0.280-11.2%$2.530$2.560$2.1908,671,600
$2.500+0.040+1.6%$2.480$2.600$2.4605,312,900
$2.460-0.090-3.5%$2.640$2.650$2.4504,725,700
$2.550-0.030-1.2%$2.550$2.610$2.52012,483,700
$2.580+0.090+3.6%$2.520$2.590$2.5004,258,000
$2.490-0.105-4.0%$2.650$2.680$2.4806,141,000
$2.595-0.315-10.8%$2.890$2.920$2.5707,233,600
$2.910+0.180+6.6%$2.720$3.040$2.7106,311,000
$2.730-0.010-0.4%$2.770$2.886$2.6707,434,600
$2.740-0.170-5.8%$2.850$2.875$2.6907,077,200
$2.910-0.360-11.0%$3.280$3.280$2.9006,511,000
$3.270-0.200-5.8%$3.430$3.480$3.2603,062,900
$3.470-0.010-0.3%$3.460$3.600$3.4004,893,100
$3.480-0.090-2.5%$3.630$3.750$3.4707,437,000
$3.570+0.270+8.2%$3.270$3.580$3.2508,042,800
$3.300+0.190+6.1%$3.000$3.315$2.8406,645,700
$3.110-0.010-0.3%$3.105$3.205$3.0803,024,500
$3.120-0.260-7.7%$3.360$3.375$3.1103,234,200
$3.380+0.130+4.0%$3.240$3.445$3.2303,800,400
$3.250+0.030+0.9%$3.200$3.270$3.1702,484,400
$3.220+0.120+3.9%$3.140$3.279$3.1103,970,737
$3.100-0.030-1.0%$3.090$3.170$3.0103,107,920
$3.130-0.060-1.9%$3.200$3.340$3.0854,402,300
$3.190+0.090+2.9%$3.040$3.240$2.9505,738,100
Ticker
BIVA:CABA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BIVA
Currency
MXN

What changed lately

Latest news

All Cabaletta Bio, Inc. news

Cabaletta Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 126 in all · newest Nov 8, 2026 · oldest 2019
Calls
1 call with a replay · 1 with a transcript · latest Nov 20, 2024
Decks
51 decks · latest Nov 9, 2026

Where Cabaletta Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CABA · Home listingNASDAQUnited StatesUSD
BOATS:CABABOATSUnited StatesUSD
BMV:CABABMVMexicoMXN
BIVA:CABA · This pageBIVAMexicoMXN

Valuation

Price/book 0.7× against a median of 6.0×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$97.45M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.89

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cabaletta Bio, Inc. · NASDAQ:CABAUS$201.9M−US$97.45Mn/an/an/a0.7×n/a0.0×1.89
AnnJi Pharmaceutical Co., Ltd. · TPEX:7754US$209.9MUS$196.0Mn/a855×n/a16.5×n/a0.0×n/a
Racura Oncology Ltd · ASX:RACUS$207.6MUS$184.9Mn/an/an/a8.6×n/a0.0×n/a
Hightide Therapeutics Inc · HKEX:2511US$204.6MUS$178.8Mn/an/an/a8.2×n/a0.9×n/a
PharmaEngine, Inc. · TPEX:4162US$204.2MUS$50.36M12.5×1.6×3.4×1.4×52.6%0.0×n/a
Bright Minds Biosciences Inc. · CSE:DRUGUS$199.5M−US$15.18Mn/an/an/a0.9×n/a0.0×0.32
Newron Pharmaceuticals S.p.A. · SIX:NWRNUS$199.5MUS$206.2Mn/a9.8×n/an/a−69.2%n/an/a
NervGen Pharma Corp. · NASDAQ:NGENUS$198.4MUS$137.8Mn/an/an/a16.4×n/a0.0×1.46
BioAge Labs, Inc. · NASDAQ:BIOAUS$196.4M−US$87.20Mn/a−10.1×n/a0.6×n/a0.0×2.06
Lineage Cell Therapeutics, Inc. · AMEX:LCTXUS$195.3MUS$152.1M111×14.0×n/a2.9×16.2%0.0×1.33
AC Immune SA · NASDAQ:ACIUUS$193.9MUS$110.5Mn/a4.7×n/a6.0×−181.9%0.1×1.56
Median of the othersUS$199.5MUS$144.9M61.9×7.3×3.4×6.0×−26.5%0.0×1.46

Forecasts

7 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
11.75 USD · Analysts' mean
EPS, year to Dec 2026
-1.29 · 6 analysts

Team and board

Officers

OfficerRole
Steven NichtbergerPresident, Chief Executive Officer, and Co-Founder
Anup MardaChief Financial Officer
Richard HenriquesIndependent Director, former CFO of Gates Foundation, former Controller at Merck
Gwendolyn BinderPresident, Science & Technology
Michael GerardGeneral Counsel
Arun DasChief Business Officer
David J. ChangChief Medical Officer
Heather Harte-HallChief Compliance Officer
Nicolette ShermanChief Human Resources Officer
Samik BasuChief Scientific Officer
Sarah YuanChief Technology Officer
Steve GavelChief Commercial Officer

Board

DirectorRole
Catherine BollardIndependent Director, George Washington University
Mark SimonIndependent Director, Torreya Partners
Richard HenriquesIndependent Director, former CFO of Gates Foundation, former Controller at Merck
Scott BrunIndependent Director, formerly at AbbVie
Shawn TomaselloIndependent Director, former CCO of Kite Pharma, Inc.
Steven NichtbergerPresident, Chief Executive Officer, and Co-Founder

Events

Calls

CallWhenStatus
Cabaletta Bio (NASDAQ:CABA) Q3 2024 Earnings CallWed, Nov 20, 2024 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−9.9%
Q2 2026Aug 13, 2026 · Before open−4.9%
Q1 2026May 14, 2026 · Before open+0.6%
Q4 2025Mar 12, 2026−6.4%
Q3 2025Nov 10, 2025 · Before open−4.7%
Q2 2025Aug 7, 2025 · Before open0.0%
Q1 2025May 15, 2025 · Before open+39.2%
Q4 2024Mar 19, 2025 · Before open+6.6%
Q3 2024Nov 14, 2024 · Before open−5.7%
Q2 2024Aug 8, 2024 · Before open−34.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · Before open+13.0%
Q4 2023Mar 21, 2024 · Before open−3.2%
Q3 2023Nov 9, 2023 · Before open+1.9%
Q2 2023Aug 10, 2023 · Before open−0.9%
Q1 2023May 11, 2023 · Before open+6.7%
Q4 2022Mar 16, 2023 · Before open+4.6%
Q3 2022Nov 10, 2022 · Before open+4.6%
Q2 2022Aug 11, 2022 · Before open+13.3%
Q1 2022May 12, 2022 · Before open+7.3%
Q4 2021Mar 17, 2022 · Before open0.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck48 slidesNov 9, 2026
Investor Presentation (September 2026)Investor deck50 slidesSeptember 2026
Investor Presentation (June 2026)Investor deck51 slidesJun 3, 2026
Investor Presentation (May 2026)Investor deck50 slidesMay 14, 2026
Investor Presentation (May 2026)Investor deck51 slidesMay 4, 2026
Investor Presentation (April 2026)Investor deck50 slidesApr 20, 2026
Investor Presentation (March 2026)Investor deck48 slidesMar 23, 2026
Investor Presentation (January 2026)Investor deck48 slidesJan 12, 2026
Investor Presentation (October 2025)Investor deck52 slidesOct 29, 2025
Investor Presentation (October 2025)Investor deck49 slidesOct 27, 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (October 2025)Investor deck51 slidesOct 9, 2025
Investor Presentation (September 2025)Investor deck42 slidesSep 3, 2025
Investor Presentation (June 2025)Investor deck40 slidesJun 11, 2025
Investor Presentation (February 2025)Investor deck27 slidesFeb 18, 2025
Investor Presentation (January 2025)Investor deck26 slidesJan 13, 2025
Technical Presentation (November 2024)Technical30 slidesNov 18, 2024
Corporate Update (November 2024)Corporate update28 slidesNov 18, 2024
Investor Presentation (October 2024)Investor deck23 slidesOct 7, 2024
Investor Presentation (August 2024)Investor deck23 slidesAug 8, 2024
Technical Presentation (June 2024)Technical43 slidesJun 14, 2024
Technical Presentation (June 2024)Technical25 slidesJun 14, 2024
Investor Presentation (May 2024)Investor deck20 slidesMay 15, 2024
Investor Presentation (January 2024)Investor deck19 slidesJan 8, 2024
Investor Presentation (November 2023)Investor deck27 slidesNov 9, 2023
Investor Presentation (October 2023)Investor deck25 slidesOct 2, 2023
Investor Presentation (September 2023)Investor deck24 slidesSep 5, 2023
Investor Presentation (July 2023)Investor deck24 slidesJul 24, 2023
Investor Presentation (May 2023)Investor deck24 slidesMay 16, 2023
Investor Presentation (May 2023)Investor deck23 slidesMay 1, 2023
Investor Presentation (March 2023)Investor deck23 slidesMar 31, 2023
Investor Presentation (March 2023)Investor deck21 slidesMar 16, 2023
Investor Presentation (January 2023)Investor deck21 slidesJan 9, 2023
Investor Presentation (December 2022)Investor deck23 slidesDec 8, 2022
Investor Presentation (November 2022)Investor deck23 slidesNov 10, 2022
Investor Presentation (October 2022)Investor deck23 slidesOct 11, 2022
Investor Presentation (September 2022)Investor deck30 slidesSep 12, 2022
Investor Presentation (August 2022)Investor deck28 slidesAug 11, 2022
Investor Presentation (May 2022)Investor deck28 slidesMay 18, 2022
Investor Presentation (March 2022)Investor deck29 slidesMar 17, 2022
Investor Presentation (March 2022)Investor deck29 slidesMar 14, 2022
Investor Presentation (January 2022)Investor deck28 slidesJan 10, 2022
Investor Presentation (December 2021)Investor deck39 slidesDec 14, 2021
Investor Presentation (November 2021)Investor deck39 slidesNov 1, 2021
Investor Presentation (August 2021)Investor deck39 slidesAug 18, 2021
Investor Presentation (August 2021)Investor deck40 slidesAug 5, 2021
Investor Presentation (June 2021)Investor deck41 slidesJun 3, 2021
Investor Presentation (May 2021)Investor deck41 slidesMay 3, 2021
Investor Presentation (April 2021)Investor deck30 slidesApr 6, 2021
Investor Presentation (June 2020)Investor deck31 slidesJun 3, 2020
Investor Presentation (February 2020)Investor deck43 slidesFeb 20, 2020

This page holds 50 of 51 decks. Open Decks

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: about US$150M · US$2.9 a share · TD Cowen +3
Dealers: TD Cowen (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), H.C. Wainwright & Co.
Buyers: Bain Capital Life Sciences; Adage Capital Management; Cormorant Asset Management; Eli Lilly and Company
May 4, 2026
Public offering of common stock and accompanying warrants (or pre-funded warrants in lieu thereof)
Update: about US$100M · US$2 a share · 1 warrant at US$2.5 for 15 months · Jefferies +2
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Cantor (co-lead)
Jun 11, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$11.00 a share on Oct 24, 2019.

Price
US$11.00 a share
Shares offered
6,800,000 shares of common stock
Offering size
US$74.8 million
Underwriters' option
Up to 1,020,000 more shares
Underwriters
MORGAN STANLEY, COWEN, EVERCORE ISI · In the order on the cover
Shares delivered
On or about Oct 29, 2019

Steps

StepWhen
Draft sent to the SEC in confidenceAug 2, 2019
Filed publiclySep 30, 2019
Amended onceOct 16, 2019
Shares registered with an exchangeOct 23, 2019
Declared effective by the SECOct 24, 2019
Final prospectus, with the priceOct 25, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Oct 25, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Research and development142.7M97.2M55.4M39.3M32.5M21.4M11.7M4.47M
Operating income-172.2M-125.1M-74.7M-54.1M-46.3M-33.8M-18.7M-6.19M
Depreciation and amortization1.65M1.71M1.43M1.18M733.0K354.0K104.0K0
EBITDA-170.6M-123.4M-73.2M-53.0M-45.6M-33.5M-18.6M-6.19M
Interest expense2.00M748.0K0
Income tax00
Net income-167.9M-115.9M-67.7M-53.0M-46.3M-33.3M-16.9M-12.2M
Earnings per share, basic-2.10-2.34-1.65-1.81-1.80-1.44-4.07-6.87
Earnings per share, diluted-2.10-2.34-1.65-1.81-1.80-1.44-4.07-6.87

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents83.0M164.0M193.2M81.6M122.2M101.4M136.2M33.0M
Short-term investments50.6M048.0M24.9M07.23M
Current assets138.9M166.7M244.5M108.8M124.5M113.5M140.6M34.0M
Property, plant and equipment1.92M2.74M2.54M2.58M1.44M890.0K815.0K
Total assets165.1M185.0M253.7M117.0M126.3M114.7M141.5M34.2M
Accounts payable6.64M4.92M4.55M2.46M2.33M1.24M920.0K603.0K
Current liabilities50.2M27.1M16.0M9.49M8.38M5.18M3.15M943.0K
Total liabilities53.0M32.7M17.5M12.4M8.38M
Shareholders' equity112.1M152.3M236.2M104.5M118.0M109.5M138.3M-10.7M
Shares outstanding100.5M50.7M47.8M29.4M28.9M24.1M24.0M3.85M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-131.1M-88.2M-53.5M-46.4M-34.1M-26.8M-16.0M-4.66M
Capital spending-1.23M-2.21M-687.0K-2.45M-1.17M-635.0K-693.0K
Free cash flow-132.3M-90.4M-54.2M-48.8M-35.3M-27.4M-16.7M
Cash from investing-50.3M47.3M-22.5M-27.2M6.00M-7.98M-693.0K
Cash from financing100.3M11.7M187.6M33.0M48.9M-24.0K119.9M37.7M
Change in cash-81.0M-29.3M111.6M-40.6M20.8M-34.8M103.2M33.0M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
8-K · Current reportNov 9, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 14, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 23, 2026Big-stake noticeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 5, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 4, 2026Big-stake noticeSEC
8-K · Current reportJun 3, 2026Current reportSEC
DEFA14A · Additional proxy materialJun 1, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
8-K · Current reportMay 14, 2026Current reportSEC
8-K · Current reportMay 4, 2026ResultsSEC
424B5 · ProspectusMay 4, 2026Offer documentSEC
8-K · Current reportMay 4, 2026Current reportSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
8-K · Current reportApr 20, 2026Current reportSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansMar 23, 2026Offer documentSEC
10-K · Annual reportMar 23, 2026Annual reportSEC
8-K · Current reportMar 23, 2026ResultsSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 18, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
8-K · Current reportOct 29, 2025Current reportSEC
8-K · Current reportOct 27, 2025Current reportSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2025Insider tradeSEC
8-K · Current reportOct 9, 2025Current reportSEC
8-K · Current reportSep 3, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveAug 18, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
CORRESP · Letter to the SECAug 13, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 13, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 11, 2025Big-stake noticeSEC
S-3 · Registration statementAug 7, 2025Offer documentSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 20, 2025Big-stake noticeSEC
8-K · Current reportJun 12, 2025Material contractSEC
424B5 · ProspectusJun 12, 2025Offer documentSEC
424B5 · ProspectusJun 11, 2025Offer documentSEC
8-K · Current reportJun 11, 2025Current reportSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
8-K · Current reportMay 19, 2025Management or board changeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
ARS · Annual report to shareholdersMay 13, 2025Annual reportSEC
DEF 14A · Proxy statementMay 13, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 30, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 1, 2025Other filingsSEC
S-8 · Registration statement for employee plansMar 31, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 31, 2025Offer documentSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
POSASRMar 31, 2025Other filingsSEC
8-K · Current reportMar 31, 2025ResultsSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
8-K/A · Current report, amendedFeb 18, 2025Current reportSEC
8-K · Current reportFeb 18, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025ResultsSEC
SC 13G/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedDec 5, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedDec 5, 2024Big-stake noticeSEC
8-K · Current reportNov 18, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 17, 2024Big-stake noticeSEC
8-K · Current reportOct 7, 2024Current reportSEC
8-K · Current reportSep 30, 2024Material contractSEC
SC 13G · Big-stake noticeAug 22, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
8-K · Current reportJun 14, 2024Current reportSEC
SC 13G · Big-stake noticeJun 10, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJun 6, 2024Big-stake noticeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
8-K · Current reportJun 4, 2024Meeting outcomeSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
ARS · Annual report to shareholdersApr 23, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2024Meeting noticeSEC
S-3ASR · Registration statementMar 21, 2024Offer documentSEC
S-8 · Registration statement for employee plansMar 21, 2024Offer documentSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024ResultsSEC
8-K · Current reportMar 20, 2024Current reportSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
8-K · Current reportFeb 1, 2024Current reportSEC
SC 13G · Big-stake noticeJan 24, 2024Big-stake noticeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
SC 13G · Big-stake noticeJan 8, 2024Big-stake noticeSEC
8-K · Current reportJan 8, 2024ResultsSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC

This page holds 200 of 454 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cabaletta Bio, Inc.’s releases · as of Oct 30, 2026

Common shares
215,720,392
Fully diluted
215,720,392

Fully diluted

LineSharesAs of
Common shares215,720,392Oct 30, 2026

Share count over time

CountShares
Oct 30, 2026215,720,392

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Jennison Associates LLC25.1M11.7%US$48.3MSep 30, 2026
T. Rowe Price23.5M10.9%US$45.1MSep 30, 2026
Bain Capital Life Sciences Investors, LLC21.2M9.8%US$40.7MSep 30, 2026
BlackRock14.4M6.7%US$27.6MSep 30, 2026
Adage Capital Partners Gp, L.L.C.14.2M6.6%US$27.2MSep 30, 2026
Vanguard10.6M4.9%US$20.3MSep 30, 2026
State Street8.05M3.7%US$15.5MSep 30, 2026
Woodline Partners LP5.2M2.4%US$9.99MSep 30, 2026
Alyeska Investment Group, L.P.4.5M2.1%US$8.64MSep 30, 2026
Cormorant Asset Management, LP4.5M2.1%US$8.64MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Geode Capital4.28M2.0%US$8.21MSep 30, 2026
Goldman Sachs4.27M2.0%US$8.19MSep 30, 2026
Citadel2.71M1.3%US$5.2MSep 30, 2026
Heights Capital Management, Inc2.5M1.2%US$4.8MSep 30, 2026
Franklin Templeton2.41M1.1%US$3.43MSep 30, 2026
Morgan Stanley2.35M1.1%US$4.51MSep 30, 2026
Opaleye Management Inc.2.32M1.1%US$4.46MSep 30, 2026
Qube Research & Technologies Ltd2.11M0.98%US$4.04MSep 30, 2026
Propel Bio Management, LLC2.05M0.95%US$3.93MSep 30, 2026
Diametric Capital, LP1.87M0.87%US$3.6MSep 30, 2026
UBS1.64M0.76%US$3.16MSep 30, 2026
Marshall Wace, LLP1.54M0.72%US$2.96MSep 30, 2026
Fidelity1.5M0.69%US$2.88MSep 30, 2026
Northern Trust1.3M0.60%US$2.49MSep 30, 2026
Sphera Funds Management LTD.1.26M0.59%US$2.43MSep 30, 2026
Cantor Fitzgerald, L. P.1.21M0.56%US$2.33MSep 30, 2026
Occam Crest Management LP1.19M0.55%US$2.28MSep 30, 2026
Dimensional1.19M0.55%US$2.28MSep 30, 2026
Two Sigma1.06M0.49%US$2.04MSep 30, 2026
Nuveen1.03M0.48%US$1.98MSep 30, 2026
Susquehanna1.01M0.47%US$1.95MSep 30, 2026
Schroders870K0.40%US$1.72MSep 30, 2026
Ameriprise828K0.38%US$1.59MSep 30, 2026
Ikarian Capital, LLC700K0.32%US$1.34MSep 30, 2026
Burkehill Global Management, LP700K0.32%US$1.34MSep 30, 2026
Squarepoint Ops LLC698K0.32%US$1.34MSep 30, 2026
TD651K0.30%US$1.29MSep 30, 2026
Millennium640K0.30%US$1.23MSep 30, 2026
Simplify Asset Management Inc.556K0.26%US$1.07MSep 30, 2026
Stonepine Capital Management, LLC520K0.24%US$998KSep 30, 2026
Superstring Capital Management LP517K0.24%US$993KSep 30, 2026
Schwab515K0.24%US$988KSep 30, 2026
KVP Capital Advisors, LP505K0.23%US$970KSep 30, 2026
Gsa Capital Partners LLP476K0.22%US$913KSep 30, 2026
XTX Topco Ltd466K0.22%US$895KSep 30, 2026
Bank of America430K0.20%US$827KSep 30, 2026
Mackenzie416K0.19%US$799KSep 30, 2026
Raiffeisen Bank International AG400K0.19%US$792KSep 30, 2026
Wellington389K0.18%US$747KSep 30, 2026
Manufacturers Life Insurance Company, The386K0.18%US$741KSep 30, 2026

This page holds 50 of 155 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
T. Rowe Price Small-Cap Value Fund, Inc.7.87M3.6%US$24.5MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF5.26M2.4%US$16.3MJun 30, 2026
Vanguard Total Stock Market Index Fund5.22M2.4%US$16.2MJun 30, 2026
PGIM Jennison Health Sciences Fund4.96M2.3%US$18.8MMay 29, 2026
iShares Russell 2000 ETF2.93M1.4%US$9.1MJun 30, 2026
PGIM Jennison Small Company Fund2.7M1.2%US$8.39MJun 30, 2026
Vanguard Extended Market Index Fund1.88M0.87%US$5.84MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.1.8M0.83%US$5.58MJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.1.39M0.64%US$4.31MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.37M0.64%US$4.26MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Small Cap Index Fund1.23M0.57%US$3.29MJul 31, 2026
iShares Biotechnology ETF1.01M0.47%US$3.13MJun 30, 2026
Franklin Biotechnology Discovery Fund877K0.41%US$2.35MJul 31, 2026
T. Rowe Price Institutional Small-Cap Stock Fund747K0.35%US$2.32MJun 30, 2026
Fidelity Extended Market Index Fund662K0.31%US$2.5MMay 31, 2026
iShares Russell 2000 Value ETF524K0.24%US$1.63MJun 30, 2026
Nuveen Equity Index Fund497K0.23%US$1.33MJul 31, 2026
iShares Russell 2000 Growth ETF487K0.23%US$1.51MJun 30, 2026
Small Cap Value Portfolio485K0.22%US$1.51MJun 30, 2026
Vanguard Explorer Fund449K0.21%US$1.2MJul 31, 2026
iShares Micro-Cap ETF374K0.17%US$1.16MJun 30, 2026
Dimensional U.S. Small Cap ETF335K0.16%US$897KJul 31, 2026
Goldman Sachs Small Cap Equity Insights Fund303K0.14%US$812KJul 31, 2026
U.S. Small Cap Portfolio301K0.14%US$808KJul 31, 2026
Fidelity Total Market Index Fund280K0.13%US$1.06MMay 31, 2026
Schwab Small-Cap Index Fund274K0.13%US$735KJul 31, 2026
Fidelity Series Total Market Index Fund224K0.10%US$849KMay 31, 2026
Master Small Cap Index Series210K0.10%US$654KJun 30, 2026
Small Company Growth Portfolio203K0.09%US$630KJun 30, 2026
PGIM Jennison Blend Fund192K0.09%US$727KMay 29, 2026
Direxion Daily S&P Biotech Bull 3X Shares179K0.08%US$479KJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF173K0.08%US$463KJul 31, 2026
Nuveen Small Cap Blend Index Fund150K0.07%US$401KJul 31, 2026
Ultra-Small Company Fund131K0.06%US$409KJun 30, 2026
EQ/2000 Managed Volatility Portfolio123K0.06%US$382KJun 30, 2026
Ultra-Small Company Market Fund123K0.06%US$382KJun 30, 2026
Goldman Sachs Small Cap Value Insights Fund115K0.05%US$310KJul 31, 2026
Schwab Total Stock Market Index Fund114K0.05%US$305KJul 31, 2026
T. Rowe Price Health Sciences Portfolio111K0.05%US$344KJun 30, 2026
Small Company Value Trust108K0.05%US$337KJun 30, 2026
Virtus Biotech Clinical Trials Etf103K0.05%US$277KJul 31, 2026
Fidelity ZERO Total Market Index Fund93,8190.04%US$251KJul 31, 2026
LVIP State Street Small-Cap Index Fund82,2000.04%US$256KJun 30, 2026
U.S. Micro Cap Portfolio80,7010.04%US$216KJul 31, 2026
Fidelity Small Cap Value Index Fund77,9900.04%US$243KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund76,8920.04%US$239KJun 30, 2026
Fidelity Nasdaq Composite Index Fund67,1790.03%US$254KMay 31, 2026
Goldman Sachs Small Cap Growth Insights Fund66,9960.03%US$180KJul 31, 2026
Fidelity ZERO Extended Market Index Fund60,3550.03%US$162KJul 31, 2026
Jacob Discovery Fund60,0000.03%US$227KMay 31, 2026

This page holds 50 of 137 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
T. Rowe Price Investment Management, Inc.13.10%28.1MOct 31, 2026Schedule 13G
Prudential Financial Inc11.40%24.3MSchedule 13G
Jennison Associates LLC11.40%24.3MMay 29, 2026Schedule 13G
Bain Capital Life Sciences Opportunities III, LP9.57%21.2MSep 30, 2026Schedule 13G
Adage Capital Management, L.P.8.43%14.2MJun 30, 2026Schedule 13G
BlackRock, Inc.7.70%13MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Shawn Tomasello
Other companies: 4D Molecular Therapeutics, Inc. (Director · Since at least Dec 10, 2020); Kalaris Therapeutics, Inc. (Director · Mar 29, 2022 – Jun 6, 2024 · Past); Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 31, 2024 · Past); UroGen Pharma Ltd. (Director · Jun 7, 2021 – Jun 7, 2021 · Past); Tcr2 Therapeutics Inc (Director · Feb 3, 2021 – Jun 1, 2023 · Past)
Director · Since at least Jul 21, 2023
Brian Daniels
Other companies: Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Bristol-Myers Squibb Company (SVP Global Dev & Med Affairs · Mar 4, 2008 – Jul 1, 2014 · Past)
Director · Oct 24, 2019 – Jun 1, 2021 · Past
Scott Brun
Other companies: Jasper Therapeutics, Inc. (Director · Since at least Jun 20, 2023); Forte Biosciences, Inc. (Director · Since at least Nov 10, 2022)
Independent Director, formerly at AbbVie · Since at least Jun 24, 2021
Gwendolyn Binder
Other companies: Instil Bio, Inc. (Board Member · Since at least Mar 18, 2021)
President, Science & Technology · Since at least Oct 24, 2019
Richard C Henriques Jr
Other companies: Arbutus Biopharma Corporation (Director · Dec 31, 2014 – May 23, 2024 · Past)
Director · Since at least Oct 24, 2019
Anup MardaChief Financial Officer · Since at least Oct 24, 2019
Arun DasChief Business Officer · Since at least Jan 5, 2022
Catherine BollardIndependent Director, George Washington University · Since at least Nov 5, 2026
David J. ChangChief Medical Officer · Since at least Oct 24, 2019
Heather Harte-HallChief Compliance Officer · Since at least Nov 5, 2026
All 20 people
PersonSeat
John Brian StalterGeneral Counsel · Oct 24, 2019 – Mar 1, 2021 · Past
Mark SimonDirector · Since at least Jun 3, 2024
Michael GerardGeneral Counsel · Since at least Sep 1, 2021
Nicolette ShermanChief Human Resources Officer · Since at least Nov 14, 2024
Richard HenriquesIndependent Director, former CFO of Gates Foundation, former Controller at Merck · Since at least Nov 5, 2026
Samik BasuChief Scientific Officer · Since at least Oct 9, 2025
Sarah YuanChief Technology Officer · Since at least Nov 5, 2026
Steve GavelChief Commercial Officer · Since at least Oct 14, 2025
Steven NichtbergerPresident, Chief Executive Officer, and Co-Founder · Since at least Aug 13, 2026
Steven NichtbergerPresident & CEO, Director · Since at least Oct 24, 2019

Open People

Log in to ask 6ix AI your own questions about Cabaletta Bio, Inc.